Skip to main content
. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837

Figure 2.

Figure 2.

Survival outcome. OS (A) and PFS (B) of 193 chemotreated patients with stage II, III, IV nodular lymphocyte-predominant Hodgkin lymphoma according to the use of rituximab. CI = confidence interval; OS = overall survival; PFS = progression-free survival.